Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Feb 23, 2015Research Conducted in Collaboration with Mount Sinai with Funding from the National Multiple Sclerosis Society and from the National Institute for Neurological Disorders and Stroke
NEWTON, Mass., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Nature Neuroscience published data...
-
Feb 5, 2015
NEWTON, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief...
-
Jan 8, 2015
NEWTON, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, selinexor...
-
Jan 7, 2015
NEWTON, Mass., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Michael G. Kauffman, MD, PhD, Chief...
-
Jan 6, 2015
NEWTON, Mass., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock...
-
Jan 5, 2015
NEWTON, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common...
-
Dec 15, 2014
NEWTON, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced today that it has been selected for addition...
-
Dec 11, 2014
NEWTON, Mass., Dec. 11, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of the SADAL study, (Selinexor and
-
Dec 8, 2014- Selinexor Demonstrates Synergy in Combination with Approved Therapies for Multiple Myeloma -
NEWTON, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical and...
-
Dec 8, 2014
NEWTON, Mass., Dec. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for...
-
Dec 4, 2014
NEWTON, Mass., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that Justin A. Renz, Executive Vice President...
-
Dec 1, 2014
NEWTON, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that its lead drug candidate, Selinexor...
-
Nov 24, 2014- Selinexor Synergy with DNA Damage Inducing Treatments Provides Potential for Improved Clinical Outcomes -
NEWTON, Mass., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of data describing its...
-
Nov 10, 2014- Reported Positive Phase 1 Clinical Data Demonstrating Early Signs of Activity for Selinexor in Several Solid Tumor Settings -
NEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter ended...
-
Nov 10, 2014
NEWTON, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the initiation of its Phase 2 study of...
-
Nov 6, 2014
NEWTON, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical and pre-clinical data for its...
-
Nov 5, 2014
NEWTON, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today that Michael G. Kauffman, MD, PhD, Chief Executive...
-
Nov 4, 2014
NEWTON, Mass., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of J. Scott Garland, Senior...
-
Oct 30, 2014
NEWTON, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company today announced it will report third quarter 2014 financial...
-
Oct 27, 2014
NEWTON, Mass., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it has expanded its operational footprint...
-
Sep 29, 2014- Selinexor Demonstrates Clinical Activity in Prostate Cancer and other Solid Tumors -
NEWTON, Mass., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today the presentation of clinical data from an...
-
Sep 25, 2014- Phase 1 Clinical Data in Prostate Cancer and Other Solid Tumors -
NEWTON, Mass., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Sep 9, 2014
NEWTON, Mass., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical and preclinical data for its...
-
Aug 8, 2014
NEWTON, Mass., Aug. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Aug 7, 2014
NEWTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Aug 7, 2014
NEWTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Aug 1, 2014
NEWTON, Mass., Aug. 1, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on nuclear transport targets, today announced that it...
-
Jun 30, 2014
NATICK, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that the underwriters of its previously announced public offering of common stock have...
-
Jun 26, 2014
NATICK, Mass., June 26, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced the pricing of its underwritten public offering of 2,647,247 shares of its common stock...
-
Jun 25, 2014
NATICK, Mass., June 25, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it has commenced an underwritten public offering of 2,200,000 shares of its common...
-
Jun 24, 2014
NATICK, Mass., June 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Jun 16, 2014
NATICK, Mass., June 16, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel,...
-
Jun 13, 2014
NATICK, Mass., June 13, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced initial Phase 1 data from patients with...
-
Jun 9, 2014
NATICK, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Jun 2, 2014
NATICK, Mass., June 2, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an...
-
May 31, 2014
NATICK, Mass., May 31, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced multiple presentations of clinical data from an...
-
May 30, 2014
NATICK, Mass., May 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
May 22, 2014
NATICK, Mass., May 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the upcoming presentation of clinical and...
-
May 20, 2014
NATICK, Mass., May 20, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
May 19, 2014
NATICK, Mass., May 19, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
May 7, 2014
NATICK, Mass., May 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
May 5, 2014
NATICK, Mass., May 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Apr 29, 2014
NATICK, Mass., April 29, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 24, 2014
NATICK, Mass., April 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 22, 2014
NATICK, Mass., April 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 21, 2014
NATICK, Mass., April 21, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 15, 2014
NATICK, Mass., April 15, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 10, 2014
NATICK, Mass., April 10, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Apr 8, 2014
NATICK, Mass., April 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Mar 5, 2014
NATICK, Mass., March 5, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Feb 27, 2014
NATICK, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Feb 26, 2014
NATICK, Mass., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Feb 6, 2014
NATICK, Mass., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Jan 22, 2014- Data Demonstrate Preliminary Evidence of Anti-Tumor Activity of Oral Selinexor in Colorectal Cancer Patients -
NATICK, Mass., Jan. 22, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Jan 14, 2014
NATICK, Mass., Jan. 14, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Jan 8, 2014
NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 20, 2013
NATICK, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Dec 11, 2013
NATICK, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
-
Dec 8, 2013
NATICK, Mass., Dec. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 7, 2013
NATICK, Mass., Dec. 7, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 5, 2013
NATICK, Mass., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Dec 2, 2013
NATICK, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
-
Nov 8, 2013
NATICK, Mass., Nov. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class...
-
Nov 5, 2013
Karyopharm Therapeutics Announces Pricing of Initial Public OfferingNATICK, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on...
-
Oct 22, 2013
Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in preclinical...
-
Oct 7, 2013
Karyopharm Therapeutics Files Registration Statement for Proposed Initial Public OfferingNatick, Mass. – October 7, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company...
-
Oct 3, 2013
Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of DirectorsNatick, Mass. – October 3, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company...
-
Aug 7, 2013
Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research...
-
Jul 31, 2013Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension
Natick, Mass. – July 31, 2013 – Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing first-in-class nuclear transport modulators for the treatment of...
-
Jun 2, 2013
Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual MeetingNatick, Mass....
-
May 28, 2013
Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA CongressNatick, Mass. – May 28, 2013 – Karyopharm Therapeutics Inc., a leader...
-
May 20, 2013
Karyopharm Therapeutics Raises $48.2 Million in Series B FinancingNatick, Mass. – May 20, 2013 – Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, today...
-
May 15, 2013
Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitors of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual MeetingNatick, Mass. – May 15, 2013 – Karyopharm Therapeutics...
-
May 9, 2013
Karyopharm Therapeutics to Present Data on Selective Inhibitors of Nuclear Export (SINE) to treat Influenza and HIV at International Congress on Antiviral Research (ICAR)Natick, Mass. May 9, 2013...
-
Mar 26, 2013
Karyopharm Therapeutics Announces 15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association of Cancer Research (AACR)...
-
Feb 5, 2013
Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & DevelopmentNatick, Mass. February 5th 2013 Karyopharm...
-
Jan 17, 2013
Karyopharm Therapeutics Initiates Treatment of Patients with Acute Myeloid Leukemia (AML) in Phase 1 Trial with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)Natick, Mass....
-
Dec 4, 2012
Karyopharm Therapeutics Initiates a Phase IIb Efficacy Study with its Novel, Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Non-Hodgkin Lymphomas (NHL)Natick, Mass....
-
Nov 13, 2012
Karyopharm Therapeutics Announces Eight Presentations on Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at the American Society of Hematology (ASH) MeetingNatick, Mass....
-
Nov 12, 2012Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Natick, Mass. November 12, 2012 Karyopharm Therapeutics Inc., leading the new field of nuclear transport modulators, announces an oral presentation on the use of its SINE CRM1 antagonists for the...
-
Oct 31, 2012
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in CancerNatick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc.,...
-
Oct 31, 2012
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in CancerNatick, Mass. October 31st, 2012 Karyopharm Therapeutics Inc.,...
-
Jul 25, 2012
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced CancersNatick, Mass. July 25, 2012...
-
May 25, 2012
Karyopharm Therapeutics Announces Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid Tumor Models at the American Society of Clinical Oncology (ASCO) MeetingNatick, Mass. May...
-
May 8, 2012
Karyopharm Therapeutics Announces Appointment of Cofounder Dr. Ronald DePinho to the National Academy of SciencesNatick, Mass. May 8, 2012 Karyopharm Therapeutics Inc., a leader in the new field...
-
Mar 15, 2012
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American...
-
Nov 8, 2011
Karyopharm Therapeutics Announces Presentations by Seven Collaborators showing Major Progress in advancing Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at American...
-
Nov 2, 2011
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for CancerNatick, Mass. – November 2, 2011...
-
Oct 11, 2011Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
Natick, Mass. – October 11, 2011 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has initiated an exclusive collaboration in the area of Selective...
-
Jan 6, 2011
Multiple Myeloma Research Foundation (MMRF) Invests $3 Million in Development of Next-Generation TreatmentsNorwalk, Conn. – January 6, 2011 The Multiple Myeloma Research Foundation (MMRF) today...
-
Jan 5, 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive OfficerNewton, Mass. – January 5, 2011 Karyopharm Therapeutics Inc., a pioneer and leader in the new field of...
-
Nov 3, 2010
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other DisordersNewton, Mass. – November...